IRLAB THERAPEUTICS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.2 SEK | +6.16% |
|
-11.81% | +49.33% |
| Sales 2023 | 5.68M 522K | Sales 2024 * | 23.65M 2.17M | Capitalization | 581M 53.4M |
|---|---|---|---|---|---|
| Net income 2023 | -178M -16.36M | Net income 2024 * | -155M -14.25M | EV / Sales 2023 | 48.9 x |
| Net cash position 2023 | 111M 10.23M | Net Debt 2024 * | 25.35M 2.33M | EV / Sales 2024 * | 25.6 x |
| P/E ratio 2023 |
-2.19
x | P/E ratio 2024 * |
-3.04
x | Employees | 31 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.58% |
More Fundamentals
* Assessed data
More news
Latest transcript on IRLAB Therapeutics AB
More press releases
| 1 day | +6.16% | ||
| 1 week | -11.81% | ||
| Current month | -28.21% | ||
| 1 month | -36.00% | ||
| 3 months | -19.42% | ||
| 6 months | +62.79% | ||
| Current year | +49.33% |
1 week
10.20
13.45
1 month
10.2016.75
Current year
7.6020.20
1 year
5.5820.20
3 years
5.5881.80
5 years
5.58110.00
10 years
5.58110.00
| Managers | Title | Age | Since |
|---|---|---|---|
Clas Sonesson
FOU | Founder | 63 | 12-12-31 |
| Chief Executive Officer | 71 | 17-05-05 | |
Nicholas Waters
FOU | Founder | 62 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jan Anders Vedin
BRD | Director/Board Member | 82 | 15-12-31 |
Rein Piir
BRD | Director/Board Member | 66 | 15-12-31 |
| Chairman | 66 | 19-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 11.2 | +6.16% | 40,046 |
| 24-04-24 | 10.55 | -8.26% | 107,324 |
| 24-04-23 | 11.5 | -7.26% | 37,691 |
| 24-04-22 | 12.4 | -6.06% | 58,486 |
| 24-04-19 | 13.2 | +3.94% | 43,535 |
Delayed Quote Nasdaq Stockholm, April 25, 2024 at 11:29 am EDT
More quotes
IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinsonâs disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinsonâs Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +49.33% | 50.25M | |
| +24.17% | 562B | |
| -6.33% | 358B | |
| +19.90% | 322B | |
| +7.95% | 297B | |
| +13.45% | 219B | |
| +6.04% | 199B | |
| -10.51% | 196B | |
| -12.26% | 149B | |
| -6.47% | 146B |
- Stock Market
- Equities
- IRLAB A Stock
